Compare DoorDash Inc (DASH) vs Medtronic PLC (MDT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DoorDash Inc vs Medtronic PLC — how do they compare? DoorDash Inc trades at $192.17 (market cap $83.07B), while Medtronic PLC trades at $87.92 (market cap $112.24B). The key difference: Medtronic PLC is the larger of the two by market cap, and Medtronic PLC pays a 3.28% dividend while DoorDash Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold DoorDash Inc for 59 Days and Medtronic PLC for 63 Days on average.
| DASH | MDT | |
|---|---|---|
Market Cap | $83.07B | $112.24B |
Volume | 3,242,567 | 105,663,236 |
Sector | Media | Health |
52-Week High | $275.44 | $105.35 |
52-Week Low | $146.60 | $73.75 |
Typical Hold Time | 59 Days | 63 Days |
Enterprise Value | $81.03B | $131.58B |
Dividend Yield | — | 3.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DoorDash (DASH) trades at $191.24, down 1.23% on the day, with strong analyst support showing 75% buy ratings and a $255.80 consensus price target. The company demonstrates robust revenue growth from $6.6B in 2022 to $13.7B in 2025, achieving profitability with net income of $935M. Recent innovations include AI-powered text ordering and drone delivery expansion, while technical indicators show the stock trading near key support at $190 with overall bullish momentum.
DoorDash presents a compelling growth story with expanding margins and strategic initiatives, though elevated valuation multiples (P/E 100.13) and recent earnings misses warrant caution. The stock offers 34% upside to analyst targets but faces regulatory scrutiny and competitive pressures in the food delivery space. Positive cash flow trends and institutional support provide fundamental strength despite near-term volatility risks.
Medtronic (MDT) trades at $85.51, down 1.81% on the day, showing bearish technical signals despite strong fundamental performance. The company has beaten earnings estimates for three consecutive quarters with Q3 2026 results pending, while maintaining robust profitability margins of 65% gross and 14% net. Recent news highlights the company's 49-year dividend growth streak and new product approvals, though technical indicators show selling pressure with the stock trading near support at $85.
MDT presents a compelling value opportunity with a 3.2% dividend yield and 14% upside to the $97.80 consensus target, though near-term technical weakness and increasing debt levels warrant caution. The company's consistent earnings beats and medical device market leadership support long-term growth, while regulatory approvals for new systems provide catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DoorDash Inc
Founded in 2013 and headquartered in San Francisco, DoorDash is an online food order demand aggregator. Consumers can use its app to order food on-demand for pickup or delivery from merchants mainly in the U.S. The firm provides a marketplace for the merchants to create a presence online, market their offerings, and meet demand by making the offerings available for pickup or delivery. The firm provides similar service to businesses in addition to restaurants, such as grocery, retail, pet supplies, and flowers. At the end of 2020, DoorDash had over 450,000 merchants, 20 million consumers, and over 1 million dashers on its platform. In 2020, the firm generated $24.7 billion in gross order volume (up 207% year over year) and $2.9 billion in revenue (up 226%).
Read more on DASH →About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →
